Table 2 Medication use after the index stroke or TIA

From: Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms

 

Index stroke (N = 313a)

Index TIA (N = 264a)

p-value

Antithrombotic treatment

 None

14 (4)

10 (4)

0.681

 Antiplatelet agent

247 (79)

239 (91)

<0.0001

  Single agent (ASA or other)

235 (75)

230 (87)

<0.0001

  Double agent (ASA + other)

12 (4)

9 (3)

0.786

 Anticoagulant agent

51 (16)

14 (5)

<0.0001

  VKA

48 (15)

13 (5)

<0.0001

  DOAC

3 (1)

1 (<1)

0.629

 Heparin

1 (<1)

1 (<1)

0.904

Cytoreductive treatment

 None

32 (10)

25 (9)

0.762

 Phlebotomy

2 (<1)

8 (3)

0.049

 Hydroxyurea

248 (79)

204 (77)

0.569

  Alone

224 (72)

193 (73)

0.680

  In combination

24 (8)

11 (4)

0.079

 Anagrelide

3 (1)

15 (6)

0.001

 Interferon

11 (4)

6 (2)

0.380

 Ruxolitinb

5 (2)

3 (1)

0.733

 Otherb

12 (4)

3 (1)

0.063

  1. Overall, 503 patients (87.2%) received either cytoreductive and antithrombotic treatments; 50 patients (8.7%) received only antithrombotic treatment (and no cytoreductive treatment), 17 patients (2.9%) received only cytoreductive treatment (and no antithrombotic treatment), and 7 patients (1.2%) received neither cytoreductive nor antithrombotic treatments
  2. ASA acetylsalicylic acid, VKA vitamin K-antagonist, DOAC direct oral anticoagulant
  3. aTwenty out of 597 patients (3%) have missing information on treatments after the index event
  4. bOther cytoreductive treatment includes pipobroman, busulphan, P32
Back to article page